Glaukos (GKOS) Competitors

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.

Do insiders & institutionals believe in GKOS or ZBH?

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 5.8% of Glaukos shares are owned by insiders. Comparatively, 1.4% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more risk & volatility, GKOS or ZBH?

Glaukos has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Do analysts prefer GKOS or ZBH?

Glaukos presently has a consensus target price of $134.67, indicating a potential upside of 39.83%. Zimmer Biomet has a consensus target price of $111.53, indicating a potential upside of 18.82%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.29

Does the media refer more to GKOS or ZBH?

In the previous week, Zimmer Biomet had 15 more articles in the media than Glaukos. MarketBeat recorded 25 mentions for Zimmer Biomet and 10 mentions for Glaukos. Glaukos' average media sentiment score of 1.60 beat Zimmer Biomet's score of 1.29 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zimmer Biomet	19 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 11.77% compared to Glaukos' net margin of -39.04%. Zimmer Biomet's return on equity of 12.99% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-39.04%	-16.53%	-10.61%
Zimmer Biomet	11.77%	12.99%	7.58%

Which has stronger valuation & earnings, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$404.52M	13.60	-$134.66M	-$2.37	-40.64
Zimmer Biomet	$7.70B	2.41	$903.70M	$4.52	20.77

Does the MarketBeat Community prefer GKOS or ZBH?

Zimmer Biomet received 453 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 66.91% of users gave Zimmer Biomet an outperform vote while only 65.19% of users gave Glaukos an outperform vote.

Company	Underperform	Outperform
Glaukos	Outperform Votes 457 65.19%	Underperform Votes 244 34.81%
Zimmer Biomet	Outperform Votes 910 66.91%	Underperform Votes 450 33.09%

Summary

Zimmer Biomet beats Glaukos on 10 of the 18 factors compared between the two stocks.